<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936608</url>
  </required_header>
  <id_info>
    <org_study_id>201901208</org_study_id>
    <nct_id>NCT03936608</nct_id>
  </id_info>
  <brief_title>ECG for Programming in CRT</brief_title>
  <acronym>EPIC</acronym>
  <official_title>Electrocardiogram for Programming in Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with heart failure and left bundle branch block benefit from Cardiac&#xD;
      Resynchronization Therapy (CRT) that delivers pacing from right ventricle (RV) and left&#xD;
      ventricle (LV) synchronously, resulting in electrical ventricular resynchrony followed by&#xD;
      revere structural cardiac remodeling and thereby reduced heart failure symptoms,&#xD;
      hospitalizations and death. It is not known if programming an individually optimized RV-LV&#xD;
      pacing offset to maximize electrical resynchrony can improve benefit from CRT.&#xD;
&#xD;
      The proposed study is a randomized controlled trial in patients undergoing implant of a CRT&#xD;
      pacemaker/defibrillator device for clinical indications to evaluate benefit of RV-LV offset&#xD;
      programming using electrocardiogram (ECG) vs. standard nominal CRT programming without RV-LV&#xD;
      offset. Patients receiving CRT devices will be randomized to either (A) active intervention&#xD;
      of programming RV-LV pacing offset to optimize ECG or to (B) active control of nominally&#xD;
      programming CRT device without RV- LV offset. The patients will be followed to evaluate&#xD;
      change in echocardiogram, quality of life, functional evaluation and a blood marker for heart&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once the eligibility for the study is determined and patient has consented for participation,&#xD;
      all study participants will undergo a baseline evaluation (within 6 weeks prior to 2 weeks&#xD;
      after CRT device implant/upgrade). Echocardiogram, quality-of-life questionnaire, 6-minute&#xD;
      hall walk, blood test, vital signs, ECGs, device interrogation and baseline demographic and&#xD;
      medical history including chart review will be obtained. After CRT device implant/upgrade,&#xD;
      participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset&#xD;
      settings including ECGs and echocardiography. A randomized assignment using a random&#xD;
      allocation table in REDCap will be used to program patients to (A) intervention or (B)&#xD;
      control RV-LV offset setting. Patients will return for study follow-up between 3-12 months.&#xD;
      Follow-up evaluations will include echocardiography, quality-of-life questionnaire, 6-minute&#xD;
      hall walk test, blood test, vital signs, ECGs, device interrogation, and follow-up medical&#xD;
      history including chart review. The patients will continue to be in extended follow-up&#xD;
      through review of their medical charts till the end of the study (12 months from date of CRT&#xD;
      implant/upgrade of the the last study participant).&#xD;
&#xD;
      Treatment and control arms: All study patients will receive standard of care clinically&#xD;
      indicated medical and device therapy per their treating physicians. After implant of a&#xD;
      clinically indicated CRT device or upgrade of a preexisting pacemaker or defibrillator device&#xD;
      to CRT system, participants will be randomized 1:1 to treatment arms (A) active intervention&#xD;
      of programming individualized RV-LV pacing offset to optimize ECG or to (B) active control of&#xD;
      nominally programming CRT device without RV-LV offset. Of note, both intervention and control&#xD;
      treatment are active FDA-approved CRT therapies and no investigational device or programming&#xD;
      will be used, and no clinically indicated treatment will be withheld from any patient. At any&#xD;
      time, if in the judgment of the patient's treating physicians or the research team, any&#xD;
      treatment including CRT programming different from the study protocol is necessitated for&#xD;
      clinical reasons, the appropriate clinically indicated changes will be made. At the end of&#xD;
      the study, if the participant is clinically doing well and the programmed CRT settings are&#xD;
      deemed clinically appropriate they will be retained, else the CRT programming may be changed&#xD;
      as per standard of care.&#xD;
&#xD;
      Enrolled participants who have a failed or unsatisfactory LV lead implant will not be&#xD;
      randomized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left Washington University&#xD;
  </why_stopped>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">November 21, 2019</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome is Echocardiographic LV End-systolic Volume.</measure>
    <time_frame>3-12 months</time_frame>
    <description>LV end-systolic volume is a reliable surrogate for clinical outcomes in clinical heart failure trials.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Cardiac Resynchronization Therapy</condition>
  <condition>Electrocardiography</condition>
  <arm_group>
    <arm_group_label>Individualized RV-LV Pacing Offset</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No RV-LV Pacing Offset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Programming individualized RV-LV pacing offset to optimize ECG</intervention_name>
    <description>After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.</description>
    <arm_group_label>Individualized RV-LV Pacing Offset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nominally programming CRT device without RV-LV offset</intervention_name>
    <description>After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.</description>
    <arm_group_label>No RV-LV Pacing Offset</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years of age who are able to give consent.&#xD;
&#xD;
          -  Diagnosis of systolic heart failure.&#xD;
&#xD;
          -  Planned to undergo new CRT device implant (or upgrade of preexisting pacemaker or&#xD;
             defibrillator device to CRT system) for standard clinical indications.&#xD;
&#xD;
          -  Expected to have over 95% heart beats resynchronized with CRT (absence of competing&#xD;
             arrhythmias or plans to not immediately activate CRT therapy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to comply with the study follow-up.&#xD;
&#xD;
          -  Life expectancy ≤1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Noheria, MBBS, SM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Sodhi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <results_first_submitted>August 5, 2020</results_first_submitted>
  <results_first_submitted_qc>November 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRT Programming</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03936608/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Individualized RV-LV Pacing Offset</title>
          <description>Programming individualized RV-LV pacing offset to optimize ECG: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.</description>
        </group>
        <group group_id="P2">
          <title>No RV-LV Pacing Offset</title>
          <description>Nominally programming CRT device without RV-LV offset: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Individualized RV-LV Pacing Offset</title>
          <description>Programming individualized RV-LV pacing offset to optimize ECG: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.</description>
        </group>
        <group group_id="B2">
          <title>No RV-LV Pacing Offset</title>
          <description>Nominally programming CRT device without RV-LV offset: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="50" upper_limit="82"/>
                    <measurement group_id="B2" value="43" lower_limit="33" upper_limit="53"/>
                    <measurement group_id="B3" value="54.5" lower_limit="33" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Randomization Groups</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome is Echocardiographic LV End-systolic Volume.</title>
        <description>LV end-systolic volume is a reliable surrogate for clinical outcomes in clinical heart failure trials.</description>
        <time_frame>3-12 months</time_frame>
        <population>Study prematurely terminated, no data analysis was performed</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized RV-LV Pacing Offset</title>
            <description>Programming individualized RV-LV pacing offset to optimize ECG: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.</description>
          </group>
          <group group_id="O2">
            <title>No RV-LV Pacing Offset</title>
            <description>Nominally programming CRT device without RV-LV offset: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome is Echocardiographic LV End-systolic Volume.</title>
          <description>LV end-systolic volume is a reliable surrogate for clinical outcomes in clinical heart failure trials.</description>
          <population>Study prematurely terminated, no data analysis was performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Individualized RV-LV Pacing Offset</title>
          <description>Programming individualized RV-LV pacing offset to optimize ECG: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.</description>
        </group>
        <group group_id="E2">
          <title>No RV-LV Pacing Offset</title>
          <description>Nominally programming CRT device without RV-LV offset: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amit Noheria</name_or_title>
      <organization>The University of Kansas</organization>
      <phone>9135889757</phone>
      <email>amit.noheria@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

